Focal therapy for prostate cancer 1996: Maximizing outcome

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 84-94

  Carroll, Peter R ^a   Presti Jr , Joseph C ^a,b   Small, Eric ^a   Roach III, Mack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CONFERENCE PAPER; CRYOTHERAPY; HUMAN; MALE; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT PLANNING;

ANDROGEN ANTAGONISTS; CRYOSURGERY; FORECASTING; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0030901699     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00174-X     Document Type: Conference Paper

References (64)

1. Kleer E, Larson-Keller JJ, Zincke H, and Oestering JE: Ability of preoperative serum prostate specific antigen value to predict pathologic stage and DNA ploidy: Influence of clinical stage and tumor grade. Urology 41: 207-216, 1993.
2. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC: The use of prostate specific antigen, clinical stage and Gleason to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
3. Israeli RS, Miller WH, and Su SL, et al: Sensitive nested transcriptase polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54: 6306-6309, 1994.
4. Katz AE, Olsson CA, and Raffo AJ, et al: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43: 765-775, 1994.
5. Bretton PR, Melamed MR, Fair WR, and Cote RJ: Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate 25: 108-114, 1994.
6. Pallavacini M, Cher E, Bowers E, Wessman M, Bolouch M, Presti J, and Carroll PR: Chromosomal aneusomies in prostate micro-metastases. (Abstr.) J Urol 153: 292A, 1995.
7. Partin AW, Piantadosi S, and Sanda MG, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45: 831-838, 1995.
8. Kavadi VS, Zagars GK, and Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 30: 279-287, 1994.
9. Goad JR, Chang SJ, Ohori M, and Scardino PT: PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 20: 727-736, 1993.
10. 1-2 prostate carcinoma: the importance of achieving an undetectable nadir PSA. (Abstr.) Int J Radiat Oncol Biol Phys 32: 230, 1995.
11. Geist RW: Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology 45: 1016-1021, 1995.
12. Epstein JL, Pizov G, and Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
13. Rosen M, Goldstone L, and Lapin S, et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148: 331-337, 1992.
14. D'Amico AV, Whittington R, and Malkowicz SB, et al: A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 30: 293-302, 1994.
15. Connolly JA, Shinohara K, Presti JC Jr, and Caroll PR: Local recurrence after radical prostatectomy: characteristics in size, location and relationship to PSA and surgical margins. Urology 47:225-231, 1996.
16. Rosen MA, Goldstone L, Lapin S, Wheeler T, and Scardino PT: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148: 331-337, 1992.
17. Ackerman DA, Barry JM, Wicklund RA, Olson N, and Lowe BA: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150: 1845-1850, 1993.
18. Smith RC, Brendler CB, and Partin A: Extended followup of the influence of wide excision of the neurovascular bundles on prognosis in men with clinically localized prostate cancer. (Abstr.) J Urol 153: 392A, 1995.
19. Littrup PJ, Mody A, Sparchu R, et al: Prostatic cryotherapy: ultrasonographics and pathological correlation in the canine model. Urology 44: 175-183, 1994.
20. Chang Z, Finkelstein JJ, Ma H, and Baust J: Development of a high-performance multiprobe cryosurgical device. Biomed Instrum Technol 28: 383-390, 1994.
21. Zippe CD: Cryosurgical ablation for prostate cancer: a current review. Semin Urol 13(2): 148-156, 1995.
22. Lee F, Bahn DK, McHugh TA, Onik GM, and Lee FT Jr: US-guided percutaneous cryoablation of prostate cancer. Radiology 192: 769-776, 1994.
23. Gage AA, Caruana JA Jr, and Montes M: Critical temperature for skin necrosis in experimental cryosurgery. Cryobiology 19: 273-282, 1982.
24. 4): preliminary results. J Urol 156:115-120, 1996.
25. Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, and Baust J: Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 72: 1291-1299, 1993.
26. Bahn DK, Lee F, Solomon MH, Gontina H, Klionsky DL, and Lee FT Jr: Prostate cancer: US-guided percutaneous cryoablation. Radiation 194: 551-556, 1995.
27. Wieder J, Schmidt JD, Casola G, van Sonnenberg E, Stainken BF, and Parsons CL: Transrectal ultrasound-guided transperineal cryoablation in the treatment of prostate carcinoma: preliminary results. J Urol 154: 435-441, 1995.
28. Coogan CL, and McKiel CF: Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. J Urol 154: 1813-1817, 1995.
29. Vijayakumar S, Awan A, and Karrison T, et al: Acute toxicity during external beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys 25: 359-371, 1993.
30. Soffen EM, Hanks GE, and Hunt MA, et al: Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radiat Oncol Biol Phys 24: 485-488, 1992.
31. Bermudez MA, Roach M, Rosenthal S, Ryu J, Hunter D, Holland J, and Phillips TL: The impact of age and conformal techniques on acute toxicity in patients receiving radiation therapy for clinically localized prostate cancer (abst). Int J Radiat Oncol Biol Phys 32: 253, 1995.
32. Hanks GE, Corn BW, and Lee WR, et al: External beam irradiation of prostate cancer: conformal treatment techniques and outcomes for the 1990s. Cancer 75: 1972-1977, 1995.
33. Hanks GE, Lee WR, Hanlon AL, Kaplan E, Epstein B, and Schultheiss T: Conformal technique dose escalation in prostate cancer: improved cancer control with higher doses (abst). Int J Radiat Oncol Biol Phys 32: 141, 1995.
34. Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Clifton L, Fuks Z, and Burman CM: Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase I dose-escalation study. J Urol 152: 1792-1798, 1994.
35. Roach M III, Meehan S, Kroll S, Weil M, Ryu J, Small EF, Margolis LW, Presti J, Carroll PC, and Phillips TL: Radiotherapy for high-grade clinically localized adenocarcinoma of the prostate. J Urol 156:1719-1723, 1996.
36. Leibel SA, Zelefsky MJ, and Kutcher GJ, et al: Three-dimensional radiation therapy in localized carcinoma of the prostate: interim report of a phase I dose-escalation study. J Urol 152: 1792-1798, 1994.
37. Roach M, Rosenthal S, Hunter D, Ryu J, Picket B, Chan A, Doggett C, Carroll PR, Narayan P, and Phillips TL: 100 consecutive patients treated for clinically localized prostate cancer by six field conformal radiotherapy: acute toxicity and lessons learned the UCSF/Davis experience (abst). 79th Meeting of the Radiology Society of North America, Chicago. Radiology 189: 183, 1993.
38. Roach M, Picket B, Rosenthal S, Verhey L, and Phillips TL: Defining treatment margins for 3-D based six field conformal (SFC) irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 28: 267-275, 1994.
39. Pickett B, Roach M, Verhey L, Horine P, Malfatti C, Akazawa C, Dea D, Varad B, Rathburn C, and Phillips TL: The value of non-uniform margins for six-field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 211-218, 1995.
40. 3) prostate cancer: minimal rectal toxicity observed using conformal therapy. Radiother Oncol 23: 53-54, 1992.
41. Haraf DJ, Rubin SJ, Sweeney P, Kuchmir FT, Sutton HG, Chodak GW, and Weichselbaum RR: Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33: 3-14, 1995.
42. Russell KJ, Caplan RJ, Laramore GE, Burnison CM, Maor MH, Taylor ME, Zink S, Davis LW, and Griffin TW: Photons vs. fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int J Radiant Oncol Biol Phys 28: 47-54, 1993.
43. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, and Biggs PJ, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32: 3-12, 1995.
44. 2 prostatic carcinoma. J Urol 154: 1096-1099, 1995.
45. Priestly JB and Beyer DC: Guided brachytherapy for treatment of confined prostate cancer. Urology 40: 37-40, 1992.
46. 4 prostate carcinoma. Int J Radiat Oncol Biol Phys 26: 551-557, 1993.
47. D'Amico AV, and Coleman CN: Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol 14: 304-315, 1996.
48. Kuban DA, Anas EM, and Schellhammer P: I-125 interstitial implantation for prostate cancer: what have we learned 10 years later? Cancer 63: 2415-2420, 1989.
49. 2 prostatic carcinoma. J Clin Oncol 14: 449-453, 1996.
50. Roy JN, Wallner KE, and Harrington PJ, et al: A CT-based evaluation method for permanent implants: application to prostate. Int J Radiat Oncol Biol Phys 26: 1163-1169, 1993.
51. Carroll PR, and Narayan PC: Treatment options for hormone-insensitive or independent prostatic carcinoma. Semin Urol 6: 332-335, 1988.
52. Alakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 71: 2782-2790, 1993.
53. Klotz L, Herr H, Morse M, and Whitmore WF: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58: 2546-2550, 1986.
54. Bruchovsky N, Rennie PS, Goldman AJ, et al: Effect of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282, 1990.
55. Goldenberg SL, Bruchovsky N, Gleave M, and Sullivan L: Intermittent androgen suppression in the treatment of prostate cancer. Urology 45:839-844, 1995.
56. Weidner N, Carroll PR, Flax J, and Folkman J: Tumor angiogenesis correlates with metastases in invasive prostate cancer. Am J Pathol 143: 401-409, 1993.
57. Heidenberg H, Sesterham IA, and Gaddipati JP, et al: Alteration of the tumor suppressor gene p58 in a high fraction of hormone refractory prostate cancer. J Urol 154: 414-421, 1995.
58. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, and Isaacs JT: Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cell. Prostate 25: 249-265, 1994.
59. Sanda MG, Ayyagari SR, and Jaffee EM, et al: Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151: 622-628, 1994.
60. Vieweg J, and Gilboa E: Gene therapy approaches in urologic oncology. Surg Oncol Clin North Am 4: 203-218, 1995.
61. Eastham JA, Hall SJ, and Sehgal I, et al: In vivo gene therapy with P53 or P21 adenovirus for prostate cancer. Cancer Res 55: 5151-5155, 1995.
62. Kahn D, Wiliams RD, and Seldin DW, et al: Radioimmunoscintigraphy with 111 Indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152: 1490-1495, 1994.
63. Bander N, Divgi C, and Theodoulou M, et al: Phase I immunolocalization trial of monoclonal antibody (mab) prost in 30 patients with prostate cancer. (Abstr.) J Urol 155: 610A, 1996.
64. Presti JC, Shinohara K, Hricak H, White S, Cher M, and Carroll PR: Clinical parameters in the pre-operative evaluation for extracapsular extension at radical prostatectomy. (Abstr.) J Urol 153: 429A, 1995.